Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Mar 2:2011:542043.
doi: 10.4061/2011/542043.

Alzheimer's disease and metals: a review of the involvement of cellular membrane receptors in metallosignalling

Affiliations

Alzheimer's disease and metals: a review of the involvement of cellular membrane receptors in metallosignalling

Pavithra C Amadoruge et al. Int J Alzheimers Dis. .

Abstract

Alzheimer's disease (AD) is a debilitating form of dementia. The hallmark protein associated with the disease is the amyloid beta (Aβ) peptide. Aggregation of Aβ has been shown to depend on interactions with metals. The recent studies now demonstrate that metals also play additional important roles in the disease process. Consequently, there may be benefit from modulating metal homeostasis. However, the role and subcellular location of metals within neurons is not well understood. There is growing evidence to suggest that metals can act at the site of cellular membrane receptors and affect cellular signaling by modulating the signal transduction of those receptors. The glutamatergic and cholinergic receptor systems, both well-known neurotransmitter systems affected in AD, have well-documented metal interactions, as do the tropomyosin-receptor kinase (Trk) family of receptors and the epidermal growth factor (EGF) receptor. In this paper, the metal interactions with these membrane receptor systems will be explored and thus the potential for membrane receptors as an intervention point in AD will be assessed.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Bush AI. Drug development based on the metals hypothesis of Alzheimer’s disease. Journal of Alzheimer’s Disease. 2008;15(2):223–240. - PubMed
    1. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Annals of Neurology. 1991;30(4):572–580. - PubMed
    1. Walsh DM, Selkoe DJ. Oligomers in the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein and Peptide Letters. 2004;11(3):213–228. - PubMed
    1. Kuo YM, Emmerling MR, Vigo-Pelfrey C, et al. Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brains. Journal of Biological Chemistry. 1996;271(8):4077–4081. - PubMed
    1. Lue LF, Kuo YM, Roher AE, et al. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer’s disease. American Journal of Pathology. 1999;155(3):853–862. - PMC - PubMed

LinkOut - more resources